ClinicalTrials.gg

Program

plamotamab

Also written as “Plamotamab” and “XmAb13676”.

Its studies are mostly in Arthritis, Rheumatoid · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Large B-Cell, Diffuse, led by Xencor.

Furthest: phase 2, since Apr 4, 20223 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xencor31 open or runningphase 2since Apr 4, 2022Sep 14, 2016Jun 2028phase 1 · NCT07230353

Also a collaborator on its studies: icon-clinical-research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2016First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT02924402 · 154 enrolled · United States, France, Korea, Republic of and more
  2. Apr 4, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05328102 · 3 enrolled · United States, France, Spain
  3. Oct 1, 2025Phase 1 study in Arthritis, RheumatoidNCT07230353 · 68 planned · Georgia, Moldova, New Zealand

Ahead

  1. Jun 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07230353

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230353Arthritis, Rheumatoid · Georgia, Moldova, New Zealand1RecruitingJun 202868
NCT05328102Lymphoma, Large B-Cell, Diffuse · United States, France, Spain2TerminatedFeb 21, 20233
NCT02924402Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Korea, Republic of and more1CompletedApr 2024154

How it is read

Names in the registry

  • “Plamotamab”, 2 entries
  • “XmAb13676”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.